Latest Ratios: P/E Ratio 0.0x · EV/EBITDA 2.0x · ROE 40.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $184M | $127M | $99M | $187M | $253M | — | — | — | — | — | — |
| Enterprise Value | $38.9B | $38.9B | $41.0B | $30.2B | $31.8B | — | — | — | — | — | — |
| P/E Ratio → | 0.03 | 0.02 | — | 0.02 | 0.04 | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — |
| P/FCF | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — |
| P/OCF | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.81 | 0.85 | 0.67 | 0.69 | — | — | — | — | — | — |
| EV / EBITDA | 2.02 | 2.02 | 2.13 | 1.68 | 1.64 | — | — | — | — | — | — |
| EV / EBIT | 2.58 | 2.57 | — | 3.14 | 3.56 | — | — | — | — | — | — |
| EV / FCF | — | 3.03 | 2.94 | 2.39 | 2.67 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.9% | 65.9% | 56.8% | 76.2% | 78.0% | 78.6% | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% |
| Operating Margin | 31.4% | 31.4% | 20.0% | 18.2% | 19.7% | 18.4% | 5.1% | 22.6% | 22.7% | 16.6% | 23.4% |
| Net Profit Margin | 14.6% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.9% | 4.8% | 22.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.4% | 40.4% | -39.0% | 26.5% | 18.9% | 18.9% | -20.1% | 10.4% | 38.1% | 7.1% | 29.0% |
| ROA | 7.7% | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.3% | 4.9% | 22.4% | 3.0% | 13.6% |
| ROIC | 19.8% | 19.8% | 12.4% | 10.1% | 10.5% | 9.0% | 2.0% | 8.7% | 26.5% | 15.6% | 18.1% |
| ROCE | 22.3% | 22.3% | 13.6% | 11.1% | 11.2% | 9.1% | 2.1% | 9.8% | 31.1% | 14.1% | 18.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.65 | 2.65 | 3.12 | 1.41 | 1.31 | 1.27 | 1.36 | 0.92 | 0.52 | 0.67 | 0.41 |
| Debt / EBITDA | 2.55 | 2.55 | 2.66 | 2.31 | 2.10 | 2.37 | 4.12 | 6.21 | 1.26 | 1.84 | 1.30 |
| Net Debt / Equity | — | 2.09 | 2.49 | 1.02 | 1.02 | 0.88 | 0.98 | 0.68 | 0.03 | 0.21 | 0.15 |
| Net Debt / EBITDA | 2.01 | 2.01 | 2.12 | 1.67 | 1.63 | 1.64 | 2.95 | 4.59 | 0.08 | 0.59 | 0.48 |
| Debt / FCF | — | 3.02 | 2.93 | 2.37 | 2.64 | 2.08 | 2.79 | 4.87 | 0.09 | 0.60 | 1.51 |
| Interest Coverage | 7.99 | 7.99 | -3.30 | 8.24 | 7.26 | 7.07 | -3.84 | 8.58 | 33.61 | 27.18 | 36.42 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | 1.26 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 5.22 | 1.55 | 1.55 |
| Quick Ratio | 1.14 | 1.14 | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 4.51 | 1.43 | 1.41 |
| Cash Ratio | 0.46 | 0.46 | 0.46 | 0.55 | 0.42 | 0.79 | 0.87 | 0.67 | 5.22 | 0.71 | 0.48 |
| Asset Turnover | — | 0.54 | 0.52 | 0.47 | 0.48 | 0.42 | 0.36 | 0.20 | 2.12 | 0.62 | 0.58 |
| Inventory Turnover | 6.11 | 6.11 | 8.16 | 4.02 | 4.33 | 4.74 | 5.68 | 1.88 | 5.48 | 5.20 | 3.99 |
| Days Sales Outstanding | — | 110.01 | 84.12 | 123.79 | 110.21 | 98.49 | 88.42 | 107.29 | 92.98 | 110.68 | 104.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Payout Ratio | 71.5% | 71.5% | — | 59.1% | 73.2% | 62.9% | — | 77.9% | 52.8% | 255.9% | 57.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 5536.0% | — | 4288.9% | 2500.0% | — | — | — | — | — | — |
| FCF Yield | 100.0% | 10079.5% | 14037.0% | 6764.5% | 4718.3% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $2.0B | $2.0B | $2.1B | $2.1B | $2.2B | $2.3B | $1.7B | $1.6B | $1.7B | $1.7B |
Patent Cliff Revenue Erosion
Based on reported figures, the company trades at an EV/EBITDA of 2.02, which appears to reflect a significant discount compared to peers like Merck and AstraZeneca, suggesting that investors are heavily pricing in the risks associated with the upcoming patent expirations of legacy blockbuster assets.
The compressed valuation multiples suggest that the market is skeptical of the company's ability to successfully transition its revenue base to the new product portfolio. Investors should monitor whether the current forward EV/EBITDA of 2.36 indicates a potential floor or if further multiple contraction is warranted as legacy revenue decay accelerates.
As reported in financial statements, the company's ROIC has struggled to gain momentum, hovering between 1.8% and 5.4% over the last ten quarters, which indicates that the massive capital outlays for inorganic growth have yet to generate returns exceeding the company's weighted average cost of capital.
The persistent gap between ROIC and historical industry standards suggests that the integration of high-cost assets is diluting overall capital productivity. This trend warrants further investigation into whether the recent acquisitions of Karuna and RayzeBio can eventually drive a meaningful inflection in returns or if they will remain a structural drag on shareholder value.
According to recent SEC filings, the cash conversion cycle has remained elevated, peaking at 109 days in 2024Q3, which suggests that the company faces structural challenges in optimizing its inventory and receivables management compared to more efficient large-cap pharmaceutical peers.
The high DSO and DIO figures imply that the company may be offering extended payment terms to maintain market share in a competitive oncology landscape. This inefficiency in working capital management appears to be a persistent headwind that limits the company's ability to convert operating profits into free cash flow.
Based on the provided data, the company's debt-to-EBITDA ratio has remained consistently high, fluctuating between 9.49 and 14.19, which indicates that the firm's reliance on debt to fund its aggressive acquisition strategy has significantly reduced its financial flexibility and increased its sensitivity to interest rate volatility.
The interest coverage ratio, which dropped as low as -26.10 in 2024Q1, highlights the precarious nature of the company's debt service capacity during periods of heavy restructuring. Investors should monitor whether the current debt levels are sustainable given the potential for mandatory price reductions under the Inflation Reduction Act.
The P/E ratio is frequently misapplied to this business model because it fails to account for the massive non-cash amortization of intangible assets resulting from the Celgene acquisition, which artificially depresses reported earnings and obscures the company's true underlying operational cash-generating power.
Analysts should instead focus on adjusted earnings or free cash flow metrics that strip out these non-recurring acquisition-related charges. Relying on GAAP P/E ratios in this context may lead to an incorrect assessment of the company's valuation, as it ignores the cash-generative nature of the core oncology and immunology franchises.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CELG-RI stock.
Bristol-Myers Squibb Company Ce's current P/E ratio is 0.0x. The historical average is 0.0x. This places it at the 67th percentile of its historical range.
Bristol-Myers Squibb Company Ce's current EV/EBITDA is 2.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 1.9x.
Bristol-Myers Squibb Company Ce's return on equity (ROE) is 40.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 26.3%.
Based on historical data, Bristol-Myers Squibb Company Ce is trading at a P/E of 0.0x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bristol-Myers Squibb Company Ce's current dividend yield is 100.00% with a payout ratio of 71.5%.
Bristol-Myers Squibb Company Ce has 65.9% gross margin and 31.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Bristol-Myers Squibb Company Ce's Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.